A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group

Barcellini, Amelia; Massaro, Maurizio; Mas, Francesca Dal; Langendijk, Johannes A.; Høyer, Morten; Calugaru, Valentin; Haustermans, Karin; Timmermann, Beate; Thariat, Juliette; Scartoni, D.; Vennarini, Sabina; Georg, Petra; Orlandi, Ester

doi:10.1016/j.ctro.2022.02.004

Cited by 3 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Although patient load for the nine responding centres remained relatively stable over the pandemic, six of the nine centres reported a decreasing trend of number of treatments delivered compared to pre-pandemic. 28 Press et al report indolent diseases were also deferred at the New York Proton Center (NYPC) and no new cases that involved respiratory motion management were initiated. 25 Mishra et al suggested delaying COVID-19-positive patients until recovered provided it is within a safe clinical window.…”

Section: Resultsmentioning

confidence: 97%

“…There were mixed results regarding PT treatment of COVID-positive patients as visualised in Table 1. Of the six articles that mentioned treatment of patients with positive COVID-19 status, three stated deferral of treatment until patient recovery or negative test result, [25][26][27] one stated infected patients were continuously treated, 28 and two stated to defer if possible, but to treat if urgent PT is required. 29,30 One article described a detailed patient selection process for patients that cannot be delayed; however, did not explicitly state treatment of infected patients.…”

Section: Resultsmentioning

confidence: 99%

“…32 Staffing limitations were reported in nine centres in Europe and the NYPC due to deployment to support COVID-19 wards, illness or quarantine requirements. 28,31 Delayed CT simulations and treatment starts due to a lockdown period and pandemic restrictions were noted by three publications. 25,26,35 Two publications reported their physics tasks, especially associated with quality assurance and control, remained unchanged during the pandemic.…”

Section: Impacts From Covid-19mentioning

confidence: 99%

“…This increase attributed to the delay in staging procedures and surgeries leading to an increase in referrals for locally advanced diseases unfit for other treatments. 28 Barcellini et al 28 noted that all responding European centres recorded a reduction of first clinical evaluations from March 2020 to February 2021 due to patients postponing, decreased referrals or cancellations in line with emergency directives. Some general modifications made to service provision included routinely screening patients prior to treatment, discussing with patients the risk of COVID-19 infection, virtual department meetings and telehealth consults, reduction of patient visitors and spacing out treatment appointments.…”

Section: Impacts From Covid-19mentioning

confidence: 99%

See 3 more Smart Citations

Proton radiation therapy patient selection and impacts of COVID‐19: A scoping review

Wood

Giles

Cunningham

et al. 2023

J of Medical Radiation Sci

View full text Add to dashboard Cite

This scoping review aimed to determine whether the COVID‐19 pandemic influenced any modifications to patient selection methods or prioritisation and services provided by proton therapy (PT) centres. This review was conducted based on the PRISMA methodology and Joanna Briggs Institute scoping review guidelines. A literature search was performed in Medline, Embase, Web of Science and Scopus, as well as grey literature. Keywords such as “COVID‐19” and “Proton Therapy” were used. Articles published from 1 January 2020 in English were included. In total, 138 studies were identified of which 11 articles met the inclusion criteria. A scoping review design was chosen to capture the full extent of information published relating to the aim. Six of 11 articles included statements regarding treatment of COVID‐19 patients. Three publications recommended deferred or alternative treatment, two indicated to treat urgent/emergency patients and one reported continuous treatment for infectious patients. Recurring impacts on PT provision included more frequent use of unconventional therapies, reduced referrals, delayed treatment starts and CT simulation, change in treatment target volumes and staffing limitations due to pandemic restrictions. Consequently, telehealth consults, remote work, reduction in patient visitors, screening procedures and rigorous cleaning protocols were recommended. Few publications detailed changes to patient selection or workflow methods during the pandemic. Further research is needed to obtain more detailed information regarding current global patient selection methods in PT, collecting this data could aid in future planning for PT in Australia.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

Section: Impacts From Covid-19mentioning

confidence: 99%

Section: Impacts From Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Proton radiation therapy patient selection and impacts of COVID‐19: A scoping review

Wood

Giles

Cunningham

et al. 2023

J of Medical Radiation Sci

View full text Add to dashboard Cite

show abstract

“…Specifically, for oncologists and cancer patients, COVID-19 outbreak led to delays in diagnosis and treatments (7), with a negative prognostic impact due to the detection of cases at a more advanced stage (8).…”

Section: Introductionmentioning

confidence: 99%

Observational study on antibody response to COVID-19 Vaccines in pAtients with gastro-entero-panCreatic Cancers and neuroendocrIne NeoplAsms on systemic TreatmEnts (VACCINATE).

Laffi¹,

D’Ecclesiis²,

Gandini³

et al. 2023

Preprint

View full text Add to dashboard Cite

The Coronavirus disease-19 (COVID-19) pandemic dramatically impacted on oncologic patients' care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated also for oncologic population. However, data about the impact of anticancer-treatments and the timing between vaccinations and systemic therapy de-livery were not available. We aimed to evaluate potential factors influencing the outcome of COVID-19 vaccination in cancer patients. We prospectively collected data of patients undergoing COVID-19 vaccination with gas-tro-entero-pancreatic and neuroendocrine neoplasms, treated at our Institute, between 03/2021 and 12/2021. We enrolled 46 patients, 63.1% males; at the time of data collection 86.9% received two-doses of Pfizer-BioNTech and the remains Moderna vaccine. All patients obtained a subsequent im-mune-response. A significantly lower values of IgG for patients treated with chemotherapy versus other anti-cancer agents (p=0.004). No significant effect on immune-response was reported for both vaccinations performed ≤7 vs >7 days from the last systemic treatment (p=0.77) and lymphocytes count (p=0.11). The findings suggest that the optimal timing for COVID-19 vaccination and lymphocytes count are not the issue but rather the quality of the subset of lymphocytes before the vaccination to deter-mine the efficacy level of immune-response in this population.

show abstract

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)

et al. 2023

View full text Add to dashboard Cite

The coronavirus disease-19 (COVID-19) pandemic dramatically impacted oncological patients’ care. Since the introduction of vaccines and the demonstration of their benefit on frail patients, COVID-19 vaccinations were indicated to also be beneficial to oncological population. However, data about the impact of anticancer-treatments and the timing between vaccinations and systemic therapy delivery were not available. We aimed to evaluate potential factors influencing the outcome of the COVID-19 vaccination in cancer patients. We prospectively collected data of patients undergoing the COVID-19 vaccination with gastro-entero-pancreatic and neuroendocrine neoplasms, treated at our institute, between 03/2021 and 12/2021. We enrolled 46 patients, 63.1% males; at the time of data collection, 86.9% had received two-doses of Pfizer-BioNTech and the rest had received the Moderna vaccine. All patients obtained a subsequent immune-response. Chemotherapy seems to determinate a significantly lower antibody response after vaccination compared to the other anti-cancer agents (p = 0.004). No significant effect on immune-response was reported for both vaccinations performed ≤7 vs. >7 days from the last systemic treatment (p = 0.77) and lymphocytes count (p = 0.11). The findings suggest that the optimal timing for COVID-19 vaccination and lymphocytes count are not the issue, but rather that the quality of the subset of lymphocytes before the vaccination determine the efficacy level of immune-response in this population.

show abstract

A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group

Cited by 3 publications

References 34 publications

Proton radiation therapy patient selection and impacts of COVID‐19: A scoping review

Proton radiation therapy patient selection and impacts of COVID‐19: A scoping review

Observational study on antibody response to COVID-19 Vaccines in pAtients with gastro-entero-panCreatic Cancers and neuroendocrIne NeoplAsms on systemic TreatmEnts (VACCINATE).

Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)

Contact Info

Product

Resources

About